Albane Frati1, Roman Rouzier2, Bénédicte Lesieur1, Gabrielle Werkoff1, Martine Antoine3, Anita Rodenas3, Emile Darai1, Elisabeth Chereau4. 1. Department of Gynecology-Obstetrics, Tenon Hospital, Paris, France. 2. Department of Gynecology-Obstetrics, Tenon Hospital, Paris, France Department of Surgical Oncology, Curie Institute, Paris, France. 3. Department of Anatomo-Pathology, Tenon Hospital, Paris, France. 4. Department of Gynecology-Obstetrics, Tenon Hospital, Paris, France Department of Surgical Oncology, Paoli Calmettes Institute, Marseille, France ED 394 - Ecole Doctorale Physiologie Physiopathologie, Paris, France EA 3499 "Transporteurs ABC et Epithéliums Normaux et Tumoraux", Paris, France chereaue@ipc.unicancer.fr.
Abstract
BACKGROUND: Somatostatin is produced by hypothalamic cells and also by tumors. We were interested to evaluate the somatostatin type 2 (SSTR2) and type 4 (SSTR4) receptor expression on a large sample cohort of breast cancer cases. MATERIALS AND METHODS: We used two different Tissue Micro Arrays (TMA) to evaluate SSTR2 and SSTR4 distribution. We evaluated the correlation between SSTR2 and SSTR4 expression and 18 tumor cells markers. We also assessed SSTR mRNA expression on an independent breast cancer population and correlated levels of SSTR2 and SSTR4 expression to molecular breast cancer subtypes. RESULTS: 268 tumors were analyzed. The tumor overexpression of estrogen receptor was significantly correlated to the expression of SSTR2 (p=0.05) and SSTR4 (p=0.04). On principal component analysis, SSTR2 subtype characterized the luminal tumor type. On an independent breast cancer population, expression of SSTR2 and SSTR4 are independent from Human Epidermal Growth Factor Receptor 2 (Her2) and correlated with luminal tumors. CONCLUSION: Expression of somatostatin receptors is a marker of luminal breast tumors. Copyright
BACKGROUND: Somatostatin is produced by hypothalamic cells and also by tumors. We were interested to evaluate the somatostatin type 2 (SSTR2) and type 4 (SSTR4) receptor expression on a large sample cohort of breast cancer cases. MATERIALS AND METHODS: We used two different Tissue Micro Arrays (TMA) to evaluate SSTR2 and SSTR4 distribution. We evaluated the correlation between SSTR2 and SSTR4 expression and 18 tumor cells markers. We also assessed SSTR mRNA expression on an independent breast cancer population and correlated levels of SSTR2 and SSTR4 expression to molecular breast cancer subtypes. RESULTS: 268 tumors were analyzed. The tumor overexpression of estrogen receptor was significantly correlated to the expression of SSTR2 (p=0.05) and SSTR4 (p=0.04). On principal component analysis, SSTR2 subtype characterized the luminal tumor type. On an independent breast cancer population, expression of SSTR2 and SSTR4 are independent from Human Epidermal Growth Factor Receptor 2 (Her2) and correlated with luminal tumors. CONCLUSION: Expression of somatostatin receptors is a marker of luminal breast tumors. Copyright
Authors: M Anlauf; M Neumann; S Bomberg; K Luczak; S Heikaus; C Gustmann; C Antke; S Ezziddin; C Fottner; M Pavel; U-F Pape; A Rinke; H Lahner; M Schott; B Cremer; D Hörsch; R P Baum; U Groh; I Alkatout; C Rudlowski; P Scheler; T K Zirbes; J Hoffmann; T Fehm; H E Gabbert; S E Baldus Journal: Pathologe Date: 2015-05 Impact factor: 1.011
Authors: Elena Trevisi; Anna La Salvia; Lorenzo Daniele; Maria Pia Brizzi; Giovanni De Rosa; Giorgio V Scagliotti; Massimo Di Maio Journal: Med Oncol Date: 2020-07-25 Impact factor: 3.064